🔎 Trials Near Me

Home › Acute Myeloid Leukemia › California

Pag-aaral pangklinika para sa Acute Myeloid Leukemia sa California

79 pag-aaral para sa Acute Myeloid Leukemia ang naghahanap ng mga kalahok sa mga site sa California.

Mga Lungsod sa California

Opisyal na teksto ng pag-aaral (English)

Olutasidenib With Azacitidine Followed by Olutasidenib Maintenance for the Treatment of IDH1-mutated Acute Myeloid Leukemia in Patients With Prior Treatment With Venetoclax Plus a Hypomethylating Agent

  • UCI Health Chao Family Comprehensive Cancer Center, Orange
  • University of California Davis Comprehensive Cancer Center, Sacramento
Nagre-recruitPhase 2
Edad 18 pataas · Lahat ng kasarian · Na-update Okt 2, 2026 · NCT07304011

Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection

  • Mission Hope Medical Oncology - Arroyo Grande, Arroyo Grande
  • PCR Oncology, Arroyo Grande
  • AIS Cancer Center at San Joaquin Community Hospital, Bakersfield
  • at 20 pa
Nagre-recruitObservasyonal na pag-aaralMalugod na tinatanggap ang malusog na boluntaryo
Edad 40 hanggang 75 · Lahat ng kasarian · Na-update Okt 2, 2026 · NCT05334069

A Phase 1 Study of Orca-Q in Recipients Undergoing Allogeneic Transplantation for Hematologic Malignancies

  • City of Hope, Duarte
  • UC Davis, Sacramento
  • Stanford Health Care, Stanford
Nagre-recruitPhase 1
Edad 12 hanggang 78 · Lahat ng kasarian · Na-update Set 29, 2026 · NCT03802695

A Phase 1 Study of AOH1996 in Patients With Relapsed/Refractory Acute Myeloid Leukemia

  • City of Hope Medical Center, Duarte
Nagre-recruitPhase 1
Edad 18 pataas · Lahat ng kasarian · Na-update Set 29, 2026 · NCT06763341

Comparing Cytarabine + Daunorubicin Therapy Versus Cytarabine + Daunorubicin + Venetoclax Versus Venetoclax + Azacitidine in Younger Patients With Intermediate Risk AML (A MyeloMATCH Treatment Trial)

  • Cedars-Sinai Medical Center, Los Angeles
  • Kaiser Permanente-Oakland, Oakland
  • Kaiser Permanente-Roseville, Roseville
  • at 2 pa
Nagre-recruitPhase 2
Edad 18 hanggang 59 · Lahat ng kasarian · Na-update Set 28, 2026 · NCT05554393

A Study of Bleximenib, Venetoclax and Azacitidine For Treatment of Participants With Newly Diagnosed Acute Myeloid Leukemia (AML)

  • City of Hope, Duarte
Nagre-recruitPhase 3
Edad 18 pataas · Lahat ng kasarian · Na-update Set 25, 2026 · NCT06852222

MYELOMATCH: A Screening Study to Assign People With Myeloid Cancer to a Treatment Study or Standard of Care Treatment Within myeloMATCH (MyeloMATCH Screening Trial)

  • Kaiser Permanente Dublin, Dublin
  • Kaiser Permanente-Fremont, Fremont
  • Kaiser Permanente Fresno Orchard Plaza, Fresno
  • at 21 pa
Nagre-recruitPhase 2
Edad 18 pataas · Lahat ng kasarian · Na-update Set 25, 2026 · NCT05564390

Study of Revumenib in Combination With Intensive Chemotherapy in Newly Diagnosed Acute Myeloid Leukemia (AML) With a NPM1 Mutation

  • Clinical Trial Site, Duarte
Nagre-recruitPhase 3
Edad 12 pataas · Lahat ng kasarian · Na-update Set 25, 2026 · NCT07211958

Venetoclax and HMA Treatment of Older and Unfit Adults With FLT3 Mutated Acute Myeloid Leukemia (AML) (A MyeloMATCH Treatment Trial)

  • Kaiser Permanente Dublin, Dublin
  • Kaiser Permanente-Fremont, Fremont
  • Kaiser Permanente Fresno Orchard Plaza, Fresno
  • at 19 pa
Nagre-recruitPhase 2
Edad 18 pataas · Lahat ng kasarian · Na-update Set 22, 2026 · NCT06317649

Comparing New Treatments for People With Newly Diagnosed Acute Myeloid Leukemia That Has an IDH2 Gene Change (A MyeloMATCH Treatment Trial)

  • UCSF Medical Center-Parnassus, San Francisco
Nagre-recruitPhase 2
Edad 18 pataas · Lahat ng kasarian · Na-update Set 22, 2026 · NCT06672146

Testing New Therapies for Patients With Acute Myeloid Leukemia Who Are Newly Diagnosed and Have Not Yet Started Treatment (A MyeloMATCH Treatment Trial)

  • Cedars-Sinai Medical Center, Los Angeles
  • Kaiser Permanente-Oakland, Oakland
  • Kaiser Permanente-Roseville, Roseville
  • at 3 pa
Nagre-recruitPhase 2
Edad 18 hanggang 59 · Lahat ng kasarian · Na-update Set 22, 2026 · NCT05554406

A Study to Compare Standard Chemotherapy to Therapy With CPX-351 and/or Gilteritinib for Patients With Newly Diagnosed AML With or Without FLT3 Mutations

  • Kaiser Permanente Downey Medical Center, Downey
  • City of Hope Comprehensive Cancer Center, Duarte
  • Loma Linda University Medical Center, Loma Linda
  • at 13 pa
Nagre-recruitPhase 3
6 Months – 21 Years · Lahat ng kasarian · Na-update Set 17, 2026 · NCT04293562

Evaluation of Two Dose Levels of Quizartinib as Maintenance in FLT3-ITD (+) Acute Myeloid Leukemia Patients in Complete Remission

  • USC Norris Comprehensive Cancer Center, Los Angeles
Nagre-recruitPhase 2
Edad 18 pataas · Lahat ng kasarian · Na-update Set 16, 2026 · NCT06824168

(Apex) Bezuclastinib in Patients With Advanced Systemic Mastocytosis

  • City of Hope Comprehensive Cancer Center, Duarte
  • UCLA Medical Center, Los Angeles
  • Stanford Cancer Institute, Stanford
Nagre-recruitPhase 2
Edad 18 pataas · Lahat ng kasarian · Na-update Set 15, 2026 · NCT04996875

Phase 1 Study of AUTX-703 in Relapsed/Refractory AML and MDS

  • City of Hope National Medical Center, Duarte
Nagre-recruitPhase 1
Edad 18 pataas · Lahat ng kasarian · Na-update Set 14, 2026 · NCT06846606

The Lowest Effective Dose of Post-Transplantation Cyclophosphamide in Combination With Sirolimus and Mycophenolate Mofetil as Graft-Versus-Host Disease Prophylaxis After Reduced Intensity Conditioning and Peripheral Blood Stem Cell Transplantation

  • City of Hope, Duarte
Nagre-recruitPhase 1/2Malugod na tinatanggap ang malusog na boluntaryo
Edad 12 hanggang 120 · Lahat ng kasarian · Na-update Set 11, 2026 · NCT05436418

A Study to Assess the Safety, Tolerability, and Antileukemic Activity of Debio 1562M in Participants With Acute Myeloid Leukemia (AML)

  • City of Hope Comprehensive Cancer Center, Duarte
Nagre-recruitPhase 1/2
Edad 18 pataas · Lahat ng kasarian · Na-update Set 11, 2026 · NCT06969430

A Study to Assess Adverse Events and How Intravenous (IV) Pivekimab Sunirine Moves Through the Body in Pediatric Participants With Relapsed or Refractory Acute Myeloid Leukemia (AML)

  • Lucile Packard Children's Hospital /ID# 276015, Palo Alto
Nagre-recruitPhase 1
6 Months – 17 Years · Lahat ng kasarian · Na-update Set 9, 2026 · NCT07306832

Xylitol Dental Wipes for the Reduction of Bloodstream Infection Risk in Children With Acute Myeloid Leukemia

  • Valley Children's Hospital, Madera
  • Kaiser Permanente-Oakland, Oakland
Nagre-recruitPhase 3
Edad 1 hanggang 25 · Lahat ng kasarian · Na-update Set 4, 2026 · NCT07022678

Study of SLS009 (Formerly GFH009) a Potent Highly Selective CDK9 Inhibitor in Patients With Hematologic Malignancies and High-Risk Newly Diagnosed AML

  • City of Hope National Medical Center, Duarte
Nagre-recruitPhase 1/2
Edad 12 pataas · Lahat ng kasarian · Na-update Set 3, 2026 · NCT04588922

Revumenib in Combination With Azacitidine + Venetoclax in Patients NPM1-mutated or KMT2A-rearranged AML

  • US-Los Angeles CA-UCLA, Los Angeles
  • US-San Francisco CA-UCSF, San Francisco
Nagre-recruitPhase 3
Edad 18 pataas · Lahat ng kasarian · Na-update Set 2, 2026 · NCT06652438

Bleximenib in Combination With Standard Induction and Consolidation Therapy Followed by Maintenance for Treatment of Patients With Acute Myeloid Leukemia (AML)

  • US-Los Angeles CA-UCLA, Los Angeles
  • US-San Francisco CA-UCSF, San Francisco
Nagre-recruitPhase 3
Edad 18 pataas · Lahat ng kasarian · Na-update Set 1, 2026 · NCT07223814

MiRisten for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia

  • City of Hope Medical Center, Duarte
Nagre-recruitPhase 1
Edad 18 pataas · Lahat ng kasarian · Na-update Set 1, 2026 · NCT07025564

CER-1236 in Patients With Acute Myeloid Leukemia (AML), Myelodysplastic Syndrome (MDS), and Myelofibrosis (MF)

  • University of California, Davis Comprehensive Cancer Center, Sacramento
Nagre-recruitPhase 1
Edad 18 hanggang 85 · Lahat ng kasarian · Na-update Ago 26, 2026 · NCT06834282

Eganelisib as Monotherapy and in Combination With Cytarabine in Relapsed/Refractory AML

  • City of Hope, Duarte
Nagre-recruitPhase 1
Edad 18 pataas · Lahat ng kasarian · Na-update Ago 25, 2026 · NCT06533761

A Phase 1b Study of Menin Inhibitor SNDX- 5613 in Combination With Daunorubicin and Cytarabine in Newly Diagnosed Patients With Acute Myeloid Leukemia and NPM1 Mutated/FLT3 Wildtype or MLL/KMT2A Rearranged or NUP98 Alterations Disease

  • UC Irvine Health/Chao Family Comprehensive Cancer Center, Orange
Nagre-recruitPhase 1
Edad 18 hanggang 75 · Lahat ng kasarian · Na-update Ago 25, 2026 · NCT05886049

The Pediatric Acute Leukemia (PedAL) Screening Trial - A Study to Test Bone Marrow and Blood in Children With Leukemia That Has Come Back After Treatment or Is Difficult to Treat - A Leukemia & Lymphoma Society and Children's Oncology Group Study

  • Kaiser Permanente Downey Medical Center, Downey
  • Loma Linda University Medical Center, Loma Linda
  • Miller Children's and Women's Hospital Long Beach, Long Beach
  • at 8 pa
Nagre-recruitPhase 1/2
Hanggang edad 22 · Lahat ng kasarian · Na-update Ago 25, 2026 · NCT04726241

Venetoclax in Children With Relapsed Acute Myeloid Leukemia (AML)

  • MemorialCare Miller Children's and Women's Hospital Long Beach, Long Beach
  • Children's Hospital of Orange County Main Campus - Orange, Orange
  • Benioff Children's Hospital - Mission Bay, San Francisco
Nagre-recruitPhase 3
29 Days – 21 Years · Lahat ng kasarian · Na-update Ago 24, 2026 · NCT05183035

Individualized AML Treatment

  • City of Hope Medical Center, Duarte
Nagre-recruitObservasyonal na pag-aaral
Edad 18 pataas · Lahat ng kasarian · Na-update Ago 21, 2026 · NCT07613385

Study of QUAIL-100 in Pediatric and Young Adult Participants With High-Risk Hematologic Malignancies Who Have Received a Hematopoietic Stem Cell Transplantation

  • Lucille Packard Children's Hospital of Stanford University, Palo Alto
Nagre-recruitPhase 1
18 Months – 39 Years · Lahat ng kasarian · Na-update Ago 21, 2026 · NCT07573111

8-Chloroadenosine in Combination With Venetoclax for the Treatment of Patients With Relapsed/Refractory Acute Myeloid Leukemia

  • City of Hope Medical Center, Duarte
Nagre-recruitPhase 1
Edad 18 pataas · Lahat ng kasarian · Na-update Ago 21, 2026 · NCT05263284

Studies to Assess Ziftomenib in Combination With Ven+Aza or 7+3 in Patients With Untreated NPM1-m or KMT2A-r AML

  • University of California, Fresno, Clovis
  • University of California, San Diego, La Jolla
  • Cedars-Sinai Medical Center, Los Angeles
  • at 2 pa
Nagre-recruitPhase 3
Edad 18 pataas · Lahat ng kasarian · Na-update Ago 20, 2026 · NCT07007312

Safety and Tolerability of Ziftomenib Combinations in Patients With Relapsed/Refractory Acute Myeloid Leukemia

  • USC Norris Comprehensive Cancer Center, Los Angeles
  • UCLA Health - Bowyer Oncology Center, Los Angeles
  • UC Irvine Health Chao Family Comprehensive Cancer Center, Orange
  • at 1 pa
Nagre-recruitPhase 1
Edad 18 pataas · Lahat ng kasarian · Na-update Ago 20, 2026 · NCT06001788

ICP-248 in Combination With Azacitidine for the Treatment in Patients With Myeloid Malignancies

  • Chao Family Comprehensive Cancer Center, University of California, Irvine, Orange
Nagre-recruitPhase 1
Edad 18 pataas · Lahat ng kasarian · Na-update Ago 18, 2026 · NCT06656494

TACrolimus Targeted Immunosuppression Cessation in ALlogeneic HCT

  • Stanford University, Palo Alto
Nagre-recruitPhase 1
Edad 18 hanggang 80 · Lahat ng kasarian · Na-update Ago 17, 2026 · NCT07302776

Niclosamide in Pediatric Patients With Relapsed and Refractory AML

  • Stanford University, Palo Alto
Nagre-recruitPhase 1
Edad 2 hanggang 25 · Lahat ng kasarian · Na-update Ago 12, 2026 · NCT05188170

Olutasidenib DDI Study in Patients With IDH1 Mutation Positive Malignancies

  • UCI Irvine Health, Orange
Nagre-recruitPhase 4
Edad 18 pataas · Lahat ng kasarian · Na-update Ago 11, 2026 · NCT07486713

Study of Revumenib, Azacitidine, and Venetoclax in Pediatric and Young Adult Patients With Refractory or Relapsed Acute Myeloid Leukemia

  • Rady Children's Hospital, San Diego
Nagre-recruitPhase 1
Edad 1 hanggang 30 · Lahat ng kasarian · Na-update Ago 3, 2026 · NCT06177067

Mula sa ClinicalTrials.gov, na-kuha noong Okt 5, 2026. Ang bawat pag-aaral ay may sariling pamantayan sa eligibility; ang koponan ng pag-aaral ang magdedesisyon kung sino ang makakasali.